Johnson & Johnson
JNJ,
has joined companies such as Merck & Co. Inc.
MRK,
Bristol Myers Squibb Co.
BMY,
and other entities in suing the federal government over Medicare’s drug-price negotiation program. Merck was first with its suit in June, alleging that the plan is a scheme to allow Medicare to obtain prescription drugs without paying fair market value, a contention the Biden administration has decried. Shares of Johnson & Johnson edged higher in the aftermarket Tuesday after ending the regular trading day flat.
